Table 2.
Immunogen | Mouse ID | zQ175 |
R6/1 | WT control |
|||
---|---|---|---|---|---|---|---|
ELISA | WB | ELISA | WB | ELISA | WB | ||
HTTexon1-Q97 plasmid | 1 | 40 | <200 | 50 | <200 | <25 | <200 |
2 | 35 | <200 | <25 | <200 | <25 | <200 | |
3 | 25 | <200 | 40 | <200 | 70 | <200 | |
4 | 40 | <200 | 45 | <200 | 30 | <200 | |
5 | 45 | <200 | <25 | <200 | 25 | <200 | |
HTTexon1-Q97 + IL-4 plasmids | 1 | 100 | <200 | <25 | <200 | 25 | <200 |
2 | 100 | <200 | <25 | <200 | 300 | <200 | |
3 | 40 | <200 | <25 | <200 | 90 | <200 | |
4 | <25 | <200 | 25 | <200 | 45 | <200 | |
5 | 175 | ND | 25 | <200 | 125 | <200 | |
HTT N586-Q82 plasmid | 1 | 900 | 2000 | 100 | 2000 | 4000 | 5000 |
2 | 600 | <200 | 900 | 2000 | 1600 | 5000 | |
3 | 250 | <200 | 100 | 2000 | 4000 | 5000 | |
4 | ND | ND | <25 | 2000 | 800 | 5000 | |
5 | 350 | 2000 | <25 | <200 | 900 | 5000 | |
6 | 2000 | 5000 | |||||
HTT N586-Q82 + IL-4 plasmids | 1 | 25 | <200 | 150 | 200 | 350 | 200 |
2 | 80 | <200 | <25 | <200 | >500 | 5000 | |
3 | 400 | <200 | 1900 | 200 | >500 | 5000 | |
4 | 60 | <200 | 100 | <200 | >500 | 5000 | |
5 | 25 | <200 | 150 | <200 | >500 | 5000 | |
6 | <25 | <200 | |||||
7 | >500 | 5000 | |||||
HTTexon1-Q97 plasmid prime + triple peptide boost | 1 | 35 | ND | 90 | ND | 100 | ND |
2 | 240 | ND | 35 | ND | <25 | ND | |
3 | <25 | ND | <25 | ND | 450 | ND | |
4 | 45 | ND | <25 | ND | 50 | ND | |
5 | <25 | ND | <25 | ND | 175 | ND | |
HTT N586-Q82 plasmid prime + triple peptide boost | 1 | 500 | ND | 35 | ND | 65 | ND |
2 | 200 | ND | <25 | ND | 50 | ND | |
3 | 80 | ND | <25 | ND | 50 | ND | |
4 | 45 | ND | <25 | ND | 60 | ND | |
5 | ND | ND | <25 | ND | 375 | ND |
Anti-Htt antibodies in sera of immunized mice were measured by ELISA or Western blotting, as in Table 1. Antibody titers >500 are shaded in gray, since overall readings were lower.
ND, Not determined.